e-learning
resources
Madrid 2019
Wednesday, 02.10.2019
Inhaled medicines and biological therapies in the current era of systemic treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future?
G. Anderson (Parkville (VIC), Australia)
Source:
International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments
Session:
Inhaled medicines and biological therapies in the current era of systemic treatments
Session type:
Hot topic
Number:
5123
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Anderson (Parkville (VIC), Australia). Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future?. International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Interference RNA as a new tool and possible future therapy for inflammatory lung disease
Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes
Year: 2005
Can we expect progress from targeted therapy of SCLC?
Source: Eur Respir Monogr 2015; 68: 234-246
Year: 2015
TB following targeted and biological therapy: can we predict it?
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020
Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
Source: Eur Respir J 2014; 44: 1011-1022
Year: 2014
Advances in target therapy for lung cancer
Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I
Year: 2014
Advances in target therapy in lung cancer
Source: Eur Respir Rev 2015; 24: 23-29
Year: 2015
Targeted therapies for lung cancer: how did the game begin?
Source: Breathe 2016; 12: 177-179
Year: 2016
Who should receive which biologic and why? Current and future approaches in severe asthma patients
Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?
Year: 2021
Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy?
Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician
Year: 2010
The future: treating specific endotypes
Source: International Congress 2015 – PG2 Asthma and COPD
Year: 2015
The future: treating specific endotypes
Source: International Congress 2016 – PG1 Asthma and chronic obstructive pulmonary disease
Year: 2016
Advances in targeted therapy: the clinicians point of view
Source: International Congress 2014 – Update on lung cancer biology for clinicians
Year: 2014
COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020
Current place and future of immunotherapy in lung cancer
Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?
Year: 2016
Treatment of interstitial lung diseases: current approaches and future directions
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept